News about

Dr. Reddy's Receives Positive CHMP Opinion from European Medicines Agency for Denosumab

Dr. Reddy's Receives Positive CHMP Opinion from European Medicines Agency for Denosumab

Dr. Reddy’s Laboratories has received a positive opinion from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) for AVT03, a proposed biosimilar to Prolia and Xgeva, moving it closer to potential marketing authorisation in the European Economic Area (EEA).

| 24/09/2025 | By 216

Roche Reports Positive Results from Phase III evERA Breast Cancer Study

Roche Reports Positive Results from Phase III evERA Breast Cancer Study

Roche has announced positive results from the phase III evERA study evaluating its investigational oral selective oestrogen receptor degrader (SERD), giredestrant, in combination with everolimus in people with oestrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer.

| 24/09/2025 | By 194

Vidal Health and SII Collaborate on HPV Vaccine Access

Vidal Health and SII Collaborate on HPV Vaccine Access

Vidal Health and Serum Institute of India (SII) have partnered to boost cervical cancer prevention, launching from 1 October 2025 a first-of-its-kind cashless platform for HPV vaccination—covering digital bookings, consent, and certification with zero paperwork.

| 24/09/2025 | By 152

Ionis Experimental Drug Zilganersen Shows Promise in Trial for Alexander Disease

Ionis Experimental Drug Zilganersen Shows Promise in Trial for Alexander Disease

Ionis Pharmaceuticals has reported positive topline results from a pivotal study of its experimental drug zilganersen in patients with Alexander disease, a rare, progressive and often fatal neurological disorder.

| 23/09/2025 | By 347

US FDA Grants Fast Track Designation to AAV Gene Therapy by Sanofi

US FDA Grants Fast Track Designation to AAV Gene Therapy by Sanofi

The US FDA has granted fast track designation to Sanofi’s SAR446268, an AAV gene therapy for juvenile and adult-onset myotonic dystrophy type 1 (DM1).

| 23/09/2025 | By 296

Datavant and Indegene Partner to Power More Efficient Clinical Trial Recruitment

Datavant and Indegene Partner to Power More Efficient Clinical Trial Recruitment

By embedding Datavant’s bespoke data enrichment capabilities into Indegene’s NEXT Patient Recruitment platform, the two companies are enabling faster trial enrollment, fewer screen failures and more efficient recruitment processes for biopharmaceutical organisations.

| 23/09/2025 | By 228

Asia Pacific Leads Global Pharmaceutical Capsule Filling Machines Market

Asia Pacific Leads Global Pharmaceutical Capsule Filling Machines Market

The Asia Pacific region dominated the global pharmaceutical capsule filling machines market in 2024, capturing a 40 percent share, according to a report by Precedence Research.

| 23/09/2025 | By 227

Jubilant Pharmova Appoints Arun Kumar Sharma as Interim CFO

Jubilant Pharmova Appoints Arun Kumar Sharma as Interim CFO

Jubilant Pharmova has Arun Kumar Sharma as Chief Financial Officer (CFO) and Key Managerial Personnel (KMP) of the company for an interim period, effective October 1, 2025. He will serve in this role until the appointment of a new CFO is finalised.

| 23/09/2025 | By 290

Qiagen and APAGE Set Regional Consensus on Rapid Molecular Testing for Gastrointestinal Infections

Qiagen and APAGE Set Regional Consensus on Rapid Molecular Testing for Gastrointestinal Infections

The two-day meeting, held on 20–21 September in collaboration with the Asia-Pacific Association of Gastroenterology (APAGE), convened key opinion leaders from Singapore, Malaysia, Thailand, Indonesia, the Philippines and Australia.

| 23/09/2025 | By 196

Alkem Launches Pertuzumab Biosimilar Pertuza in India for HER2-Positive Breast Cancer

Alkem Launches Pertuzumab Biosimilar Pertuza in India for HER2-Positive Breast Cancer

Alkem Laboratories has introduced Pertuza, a biosimilar of pertuzumab, in India for the treatment of HER2-positive breast cancer. The drug is supplied as a 420 mg/14 mL injection and is developed and manufactured domestically.

| 23/09/2025 | By 429

 
 

 

 

We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.

More information: Privacy Policy

 pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members